Comprehensive Medical Weight Loss Denver
Weight Loss Strategies for patients of Clinical Nutrition Center in Denver, CO.
Sleep deprivation adds 385 calories a day to your intake — not because you lack willpower, but because your hormones are working against you. Here's what the science says.
Teenagers With Obesity Aren’t Waiting for the Operating Room Anymore A study published in JAMA Pediatrics on July 20, 2026, by Messiah and colleagues has a number that should make every pediatrician in Colorado pause. GLP-1 receptor agonist use among…
For years, patients asked about a pill version of GLP-1 medication. “Anything I can swallow instead of inject?” The answer used to be: not really. Oral semaglutide existed, but the fine print made it impractical for most people. That changed…
Good news for Colorado state employees: GLP-1 medications for weight loss are a covered benefit again. Effective May 1, 2026, the State of Colorado reinstated GLP-1 coverage for obesity treatment under its employee health plan — covering approximately 30,000 state…
Stopping vs. Switching — They’re Not the Same Thing Before anything else: there’s an important distinction between stopping a GLP-1 and switching from one GLP-1 to another. Patients often conflate them — and the distinction matters enormously for your plan.…
Let me start with a number that should get your attention: 28.7%. That’s how much body weight participants lost in the latest Phase 3 trial of retatrutide, Eli Lilly’s investigational triple-agonist obesity medication. At 68 weeks, the average weight loss…
Medicare GLP-1 Bridge: One Month In — What Colorado Patients Need to Know The Medicare GLP-1 Bridge launched on July 1, 2026. One month in, my phone rings with the same three questions: Do I qualify? Will it really cost…
If you’re starting a GLP-1 like semaglutide or tirzepatide here in Denver, the question I hear most isn’t “how much will I lose.” It’s “what will it feel like?” Fair. Nobody wants to walk in blind. Roughly 40 to 70…
*A new Gallup poll puts the U.S. adult obesity rate at 36.4% — down from a peak of 39.9% in 2022. One in nine Americans now takes a GLP-1 medication. A Denver obesity physician takes stock.* — In 2022, 39.9%…
You’ve decided to pursue GLP-1 therapy—smart move. But now comes the fork in the road: needle or pill? If your primary care doctor just said “pick whichever you prefer,” they weren’t wrong, but they also weren’t telling you the whole…
